Avricore Health (AVCRF) Return on Sales (2009 - 2025)

Avricore Health has disclosed Return on Sales across 16 years of filings, most recently posting 0.01% for Q3 2025.

• In Q3 2025, Return on Sales fell 2.0% year-over-year to 0.01%; the TTM figure through Sep 2025 stood at 0.0% (changed 0.0% YoY), while the FY2025 annual figure was 0.0%, changed 0.0% from the prior year.
• Return on Sales improved to 0.01% in Q3 2025, from 0.02% in the prior quarter.
• Over the last five years, Return on Sales for AVCRF reached as high as 0.87% in Q4 2021 and fell as low as 0.07% in Q3 2021.
• The 5-year median for Return on Sales is 0.0% (2023), against an average of 0.04%.
• Annual changes were most pronounced in 2021 — Return on Sales jumped 87 bps — and 2022, when it plunged 85 bps.
• A 5-year view of Return on Sales shows it stood at 0.87% in 2021, then plunged by 98 bps to 0.02% in 2022, then sank by 81 bps to 0.0% in 2023, then slipped by 2 bps to 0.0% in 2024, then slumped by 459 bps to 0.01% in 2025.
• According to Business Quant data, Return on Sales over the past three periods registered 0.01%, 0.02%, and 0.01% for Q3 2025, Q2 2025, and Q1 2025 respectively.